These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A Unique Presentation of Serum Sickness From Rabbit Antithymocyte Globulin in a Kidney Transplant Recipient. Asterita R; Thoguluva Chandrasekar V; Kohlitz P Am J Ther; 2017; 24(4):e491. PubMed ID: 27661753 [No Abstract] [Full Text] [Related]
4. Administration of Antithymocyte Globulin (Rabbit) to Treat a Severe, Mixed Rejection Episode in a Pregnant Renal Transplant Recipient. Kutzler HL; Ye X; Rochon C; Martin ST Pharmacotherapy; 2016 Apr; 36(4):e18-22. PubMed ID: 26892892 [TBL] [Abstract][Full Text] [Related]
5. Serum sickness after treatment with rabbit antithymocyte globulin in a heart transplant recipient with previous rabbit exposure. Lyons P; Castillo J; Potter L; Fedson S Transplant Proc; 2015; 47(1):198-200. PubMed ID: 25645803 [TBL] [Abstract][Full Text] [Related]
6. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal. Saull HE; Enderby CY; Gonwa TA; Wadei HM Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849 [TBL] [Abstract][Full Text] [Related]
7. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Deeks ED; Keating GM Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926 [TBL] [Abstract][Full Text] [Related]
8. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D; N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248 [TBL] [Abstract][Full Text] [Related]
9. Serum sickness after antithymocyte globulin administration in a cardiac transplant patient. Rizkallah J; Cordova F; Malik A; Zieroth S Transplantation; 2012 Dec; 94(11):e68-9. PubMed ID: 23222743 [No Abstract] [Full Text] [Related]
10. Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival. Couvrat-Desvergnes G; Salama A; Le Berre L; Evanno G; Viklicky O; Hruba P; Vesely P; Guerif P; Dejoie T; Rousse J; Nicot A; Bach JM; Ang E; Foucher Y; Brouard S; Castagnet S; Giral M; Harb J; Perreault H; Charreau B; Lorent M; Soulillou JP J Clin Invest; 2015 Dec; 125(12):4655-65. PubMed ID: 26551683 [TBL] [Abstract][Full Text] [Related]
11. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Heilman RL; Reddy KS; Mazur MJ; Moss AA; Post DJ; Petrides S; Mulligan DC Transplant Proc; 2006 Jun; 38(5):1307-13. PubMed ID: 16797289 [TBL] [Abstract][Full Text] [Related]
16. Effects of Ideal Versus Total Body Weight Dosage of Rabbit Antithymocyte Globulin on Outcomes of Kidney Transplant Patients With High Immunologic Risk. Vacha M; Gommer J; Rege A; Sanoff S; Sudan D; Harris M Exp Clin Transplant; 2016 Oct; 14(5):511-517. PubMed ID: 26742693 [TBL] [Abstract][Full Text] [Related]
17. A Comparison of Two Types of Rabbit Antithymocyte Globulin Induction Therapy in Immunological High-Risk Kidney Recipients: A Prospective Randomized Control Study. Burkhalter F; Schaub S; Bucher C; Gürke L; Bachmann A; Hopfer H; Dickenmann M; Steiger J; Binet I PLoS One; 2016; 11(11):e0165233. PubMed ID: 27855166 [TBL] [Abstract][Full Text] [Related]